Disclaimer: This is a user generated content submitted by a member of the WriteUpCafe Community. The views and writings here reflect that of the author and not of WriteUpCafe. If you have any complaints regarding this post kindly report it to us.
Lapatinib is a small-molecule kinase inhibitor that targets the epidermal growth factor receptor and the human epidermal growth factor receptor 2 (HER2). The cost of lapatinib depends on several factors including the patient's health, the severity of disease, and the type of brand (either generic or branded). Lapatinib was approved by the FDA to treat patients with advanced/metastatic HER2 breast cancer and who have taken prior therapy including an anthracycline, trastuzumab, and taxane.
